We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.96%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.19B
AUM Growth
-$667M
Cap. Flow
-$151M
Cap. Flow %
-3.6%
Top 10 Hldgs %
47.69%
Holding
131
New
13
Increased
16
Reduced
22
Closed
21

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$101M
2
SION
Sionna Therapeutics
SION
+$60.5M
3
AXSM icon
Axsome Therapeutics
AXSM
+$44.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.6M
5
UNH icon
UnitedHealth
UNH
+$35.9M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$117M
2
MRK icon
Merck
MRK
+$82.6M
3
BIIB icon
Biogen
BIIB
+$77.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$61.2M
5
UHS icon
Universal Health Services
UHS
+$48.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$334M 7.96%
2,718,735
– –
EWTX icon
2
Edgewise Therapeutics
EWTX
$4.34B
$330M 7.88%
15,021,721
– –
BSX icon
3
Boston Scientific
BSX
$68.5B
$284M 6.77%
2,813,200
-347,100
-11% -$35M
LLY icon
4
Eli Lilly
LLY
$1.09T
$279M 6.65%
337,600
– –
ELVN icon
5
Enliven Therapeutics
ELVN
$3.84B
$157M 3.73%
7,959,538
– –
ISRG icon
6
Intuitive Surgical
ISRG
$130B
$144M 3.44%
291,000
-110,700
-28% -$61.2M
SYK icon
7
Stryker
SYK
$133B
$134M 3.19%
359,200
+14,800
+4% +$5.63M
ARGX icon
8
argenx
ARGX
$54.6B
$122M 2.92%
206,700
+17,000
+9% +$10.7M
EW icon
9
Edwards Lifesciences
EW
$48.2B
$111M 2.65%
1,532,000
+386,698
+34% +$27.7M
UNH icon
10
UnitedHealth
UNH
$389B
$105M 2.51%
201,200
+70,300
+54% +$35.9M
SPRY icon
11
ARS Pharmaceuticals
SPRY
$563M
$104M 2.49%
8,288,510
– –
NBIX icon
12
Neurocrine Biosciences
NBIX
$18.4B
$103M 2.46%
934,640
-3,480
-0.4% -$441K
PFE icon
13
Pfizer
PFE
$144B
$97.6M 2.33%
+3,850,200
New +$101M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$38.5B
$93.5M 2.23%
346,100
-69,500
-17% -$17.9M
ITGR icon
15
Integer Holdings
ITGR
$3.41B
$78.2M 1.86%
662,500
+87,500
+15% +$11.5M
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$124B
$77.5M 1.85%
159,900
+8,900
+6% +$4.15M
NTRA icon
17
Natera
NTRA
$36.1B
$77.4M 1.84%
547,000
+134,000
+32% +$21.5M
IONS icon
18
Ionis Pharmaceuticals
IONS
$9.14B
$76.6M 1.83%
2,540,136
-277,211
-10% -$9.08M
IRON icon
19
Disc Medicine
IRON
$2.85B
$70.2M 1.67%
1,415,020
-370,551
-21% -$20.6M
TMO icon
20
Thermo Fisher Scientific
TMO
$214B
$64.2M 1.53%
129,000
+44,600
+53% +$24.2M
THC icon
21
Tenet Healthcare
THC
$22.6B
$62.5M 1.49%
465,000
-327,000
-41% -$43.1M
CYTK icon
22
Cytokinetics
CYTK
$10.8B
$60.7M 1.45%
1,509,205
-74,800
-5% -$3.44M
CGON icon
23
CG Oncology
CGON
$6.41B
$60.5M 1.44%
2,471,994
+1,040,880
+73% +$29.3M
AVBP icon
24
ArriVent BioPharma
AVBP
$1.4B
$56M 1.33%
3,027,328
– –
RNAM
25
DELISTED
Avidity Biosciences
RNAM
$53.5M 1.28%
1,812,886
+700,000
+63% +$21.8M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2025 Portfolio in Review

As of Q1 2025, OrbiMed held 131 positions worth $4.19B, down 14% from $4.86B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

OrbiMed withdrew a net $151M in Q1 2025, closing 21 positions and reducing 22 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Pfizer worth $97.6M.

  • OrbiMed's largest Q1 2025 buy was Pfizer: 3,850,200 shares worth $97.6M.
  • OrbiMed added most to UnitedHealth in Q1 2025, an estimated $35.9M increase.
  • OrbiMed's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $61.2M.
  • OrbiMed fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 48% of its $4.19B portfolio in Q1 2025.
  • OrbiMed opened 13 new positions and closed 21 in Q1 2025.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $4.19B.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.